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Abstract: Squamous cell carcinoma of the head and neck, SCCHN, is a heterogeneous group of tu-
mours not only concerning the site of origin but also regarding aetiology. The 5-year survival for the 
whole group of SCCHN tumours has not significantly improved over the last 20-25 years. Apart from 
tumour spread to lymph nodes, N status, gains and losses of specific chromosomes are the only fac-
tors shown to be independent prognostic markers for these tumours. Worldwide, an increasing num-
ber of people ≤ 40 years are seen being affected by tongue SCC, the most common tumour within the 
SCCHN group. Even without any clinical signs of metastasis, up to 30% of all tongue SCC have his-
tologically detectable spread to lymph nodes.  
In this mini review, field cancerization, tumour microenvironment, the so called EMT (epithelial 
mesenchymal transition) process and the role of viruses in development of SCCHN are discussed as 
well as potential new therapeutic targets.  
For the group of tongue SCC, with the increasing incidence seen in young patients and particularly 
women, new data with impact on prognosis and treatment are urgently needed. But as long as data 
from the analyses of several sub sites are presented as valid for the whole group of tumours, this vital 
point is missed.  
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1. SQUAMOUS CELL CARCINOMA OF THE HEAD 
AND NECK, SCCHN, AND SUB-SITES 
The group squamous cell carcinoma of the head and 
neck, SCCHN, encompasses tumours in different anatomical 
locations, such as oral cavity, pharynx, larynx, nasal cavity, 
paranasal sinuses and salivary glands. Of the SCCHN tu-
mours located in the oral cavity, the majority are tumours in 
the tongue, which is a complicated organ with varying 
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histology. The tongue is covered by squamous epithelium 
which on the upper surface has developed into specific papil-
lary structures, some of which harbour taste buds. Most SCC 
of the tongue develop on the lateral border, where the two 
types of epithelia meet. Interestingly, it is clear that tongue 
SCC differ from SCC in other intra-oral sites regarding, for 
example, expression of proteins and miRNAs [1, 2]. Also in 
clinically normal tissue adjacent to tumour, a difference can 
be seen based on the sub-site, showing the need to take sub-
site into consideration in studies of the group of SCCHN, 
also when concentrating on intraoral SCC only [1, 2].  
All over the world, there is a worrying trend with an in-
creasing number of young people (≤ 40 years) being affected 
by tongue SCC [3]. In the whole group of SCCHN tumours, 
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there is no difference in the prognosis between young and 
“normal aged” patients [4], whereas among tongue SCC, a 
significantly higher frequency of recurrence has been re-
ported in young compared to old patients [5].  
The 5-year survival for the whole group of SCCHN tu-
mours has not significantly improved over the last 20-25 
years. One factor of major prognostic importance is the pres-
ence of lymph node metastases (N-status). Even without any 
clinical signs of metastasis, up to 30% of all tongue SCC 
have histologically detectable spread to lymph nodes [6, 7]. 
This is possible due to a well developed net of lymph vessels 
in the tongue, which also crosses the midline, easing spread 
to the contra lateral side [6]. 
Even if there are several hundreds of published reports 
concerning prognostic factors only a few such as gains of 
chromosome 3q21-29, 11q13 and loss of 8p21-22, have 
shown to be independent prognostic markers, with even 
higher significance than clinical node status [8].  
2. FIELD CANCERIZATION AND TUMOUR MI-
CROENVIRONMENT 
For tongue SCC and other intra-orally located SCC, the 
so called ”field effect” or ”field cancerization” is a well 
known phenomenon. Since it was first described 60 years 
ago, the definition has slightly changed and now, based on 
molecular knowledge, is “one or more areas consisting of 
epithelial cells that have genetic alterations” [9]. Thus, not 
only the tumour itself but also the surrounding tissue shows 
genetic changes related to the neoplastic process. For intra-
oral SCC, such genetically changed fields can be detected 
within 7 cm from the tumour [9], meaning that practically 
the whole oral cavity is affected. These changes can not be 
seen in routine histology, but could be of great value for 
early detection of a relapse or a newly arising tumour. One 
example of a field cancerization change is deregulation of 
microRNA 424, miR-424. miRNAs which comprise around 
3% of the known genes in the human genome can either 
have tumour suppressor function or act as oncogenes (on-
comiRs) [10], and regulate up to 30% of all human genes 
[11]. For miR-424, levels in tongue tissue adjacent to the 
tumour were significantly lower compared to both tumour 
and normal tongue tissue from healthy volunteers indicating 
that, apart from being a marker of field cancerization, miR-
424 could also be important for tumour development [12]. 
However, comparing miRNA profiles from different studies 
of tongue SCC does not give a uniform pattern of up- and 
down-regulated miRNAs [7], and results also vary in cell 
lines derived from tongue SCC. The thought of using miR-
NAs as both biomarkers and potential therapeutic targets 
remains tempting and investigations are ongoing [13]. A 
complicating factor is the potential ability of each individual 
miRNA to target hundreds or even thousands of different 
mRNAs [10], a fact that must be taken into consideration 
when planning new therapeutic strategies. 
At this stage the role of miRNAs as biomarkers seems 
clear, and mapping alterations in expression of them in tu-
mour and the surrounding field in individual patients pro-
vides information about abnormalities and also shows how 
the tumour influences its’ stroma, the so called tumour mi-
croenvironment. 
In connection to most tumours a host response in the 
form of inflammation can be seen. Tongue SCC patients 
with a dense inflammatory infiltrate as judged by the grading 
introduced by Brandwein-Gensler and coworkers [14,15] 
have better prognosis compared to patients with tumours 
with limited or no inflammatory response [5]. Regulation of 
inflammation in correlation to tumours is a complicated 
process. One important factor is OAS2 (oligoadenylate syn-
thetase 2), which plays a role in down-regulation of the spe-
cific T-cell response [16]. When comparing tongue SCC to 
tonsillar SCC, tongue tumours show considerably higher 
expression of OAS2 [56], indicative of a less active T-cell 
response in this disease, which also has a worse prognosis.  
Another factor involved in the inflammatory response is 
PD-L1, programmed death ligand 1, which by binding to the 
co-receptor PD-1 on T-cells can inhibit T-cell proliferation 
and thus a proper inflammatory response [17]. As levels of 
PD-L1 are upregulated in many types of tumours and its ex-
pression has been correlated with poor prognosis, blocking 
of the receptor with antibodies is a potential way of enhanc-
ing immune reactivity against tumours. So far, pre-clinical 
studies from blocking of the PD-L1:PD-1 pathway in 
SCCHN show promising results with increased anti-tumour 
immune responses. To have effect, there is need for an acti-
vated immune system in the microenvironment of the tumour 
[18]. 
3. TUMOUR SPREAD 
In the process of tumour spread, Epithelial Mesenchymal 
Transition, EMT, is important, at least in vitro, whereas its 
existence in vivo is not convincingly proven so far [19]. Dur-
ing EMT, cells of epithelial origin achieve mesenchymal 
characteristics, measured as loss and gain of epithelial- and 
mesenchymal-specific markers, respectively. This more 
mesenchymal appearance eases spread through a mesenchy-
mal environment like the connective tissue. One epithelial-
specific factor down-regulated during EMT is E-cadherin, an 
epithelial calcium dependent adhesion molecule [20] impor-
tant in cell adhesion through binding to β-catenin [21,22]. 
When E-cadherin is down regulated, β-catenin is no longer 
attached to the cell membrane and is instead transported into 
the nucleus where it can act as an oncogenic transcription 
factor [23]. A connection between levels of E-cadherin and 
prognosis has been seen in SCCHN, where tumours with low 
expression show poor prognosis in contrast to tumours with 
high expression showing good prognosis [24].  
When evaluating the effect of anti PDL-1 therapy in 
melanomas, it was found that β-catenin within the tumours 
caused exclusion of T-cells and thus also resistance to this 
therapy [25]. If results are valid also in other tumours, target-
ing of β-catenin could be used to gain an immunostimulatory 
effect in SCCHN. 
A protein known to enhance cell motility and tumour in-
vasion in for example SCC is the transmembrane protein 
podoplanin, PDPN, [26] which apart from being expressed 
by certain tumour cells, is also expressed in endothelial cells 
in lymph vessels. Young patients with tongue SCC (≤ 40 
years) show significantly higher levels of this protein com-
pared to old patients, indicative of a specific role for podo-
planin in young patients [27]. The reason for this is not 
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known, but as a PDPN-antibody and lectin have shown the 
ability to inhibit PDPN expression and thus also motility and 
invasion [28], PDPN is a potential therapeutic target in the 
group of young patients with tongue SCC and a known 
worse prognosis [27]. 
4. VIRUS 
4.1. Human Papilloma Virus, HPV 
Based on the increase seen in oropharyngeal cancers 
caused by HPV [29, 30], the importance of viruses in devel-
opment of SCCHN has been a focus for discussion. Both 
oropharyngeal and oral SCC infected with HPV have shown 
better outcome compared to non-infected tumours [31, 32]. 
In the clinical situation, detection of the p16 protein has been 
used as a surrogate marker for high risk HPV in many pa-
thology laboratories, especially types 16, 18, 31, 33, 34, 35, 
39, 51, 52, 56, 58, 59, 66, 68 and 70, but p16 can also be 
expressed independently of HPV [33]. In tonsillar SCC, ex-
pression of p16 shows high concordance with HPV infection 
[34], whereas HPV16 is not detected in tongue SCC by in 
situ hybridization, but p16 is expressed, and thus there is no 
correlation between HPV16 and p16 expression in this tu-
mour type [35]. Whether this completely excludes involve-
ment of high risk HPV in tongue SCC is hard to say, as it 
must be kept in mind that smaller amounts of virus may need 
more sensitive methods for detection.  
The reason for less HPV-infected tongue SCC compared 
with tonsillar SCC is not easily explained, especially not as 
the possibility for the virus to enter the tissue seems compa-
rable between the two, judged by presence of the HPV-
receptor syndecan-1 [36] which is equally expressed in 
tongue and tonsil [35].  
Looking at p16 expression irrespective of HPV-status, an 
improved prognosis is seen for p16-positive tongue SCC. 
This could be due to many causes, for example the ability of 
p16 to induce a senescent phenotype resulting in slower tu-
mour growth, or the role of p16 in repair of DNA double 
strand breaks [33, 37, 38, 39]. The use of p16 as a clinical 
indicator of worse prognosis particularly in patients ≤ 40 
years with tongue SCC could thus be of value [35] advocat-
ing more aggressive treatment. 
With the ongoing vaccination programme against high 
risk HPV types (primarily introduced to prevent cervical 
cancer) it will be interesting to see if, in the long run, this 
affects the increasing frequency of tongue SCC seen among 
young people, and primarily women. Such a decrease would 
thus indicate a role for HPV also in development of tongue 
SCC, but in doses too low to be detected with the common 
methods used today. If this is seen, a wider programme for 
vaccination could be implicated. 
4.2. Epstein Barr Virus, EBV 
Epstein Barr virus, EBV, or human herpesvirus 4, is one 
of the most common human viruses found all over the world. 
During their life time, the majority of people at some point 
become infected. In general the primary infection occurs in 
the first few years of life and is asymptomatic, but infection 
at later stages, typically in adolescents or young adults, 
manifests as infectious mononucleosis in around half of the 
cases [40]. A strong association between EBV infection and 
nasopharyngeal cancer has been known for many years.  
EBV-infected cells, where B-cells are the primary target, 
express so called EBV-encoded RNAs, EBERs, which are 
small non coding RNAs of two types, EBER-1 and EBER-2 
[41]. Detection of EBERs by in situ hybridization is there-
fore used as a sign of EBV infection in tissue. As EBERs can 
induce transcription of growth factors in different cell types, 
they are important contributors to carcinogenesis in tissue of 
lymphoid as well as epithelial origin [42].  
In clinically healthy normal oral mucosa, EBV infection 
is rarely detected, whereas in the whole group of oral SCC 
up to 40% of tumours are infected [43]. Looking at tongue 
SCC specifically, 67% were positive, all showing signals 
from epithelial cells as well as lymphocytes using in situ 
hybridization. In only two cases, signals from lymphocytes 
only were seen, showing the high propensity of epithelial 
cells to be EBV infected [44]. In contrast, our own recent 
data showed no evidence of EBV infection in SCC of the 
mobile tongue [57]. 
More recently the importance of interaction between dif-
ferent types of viruses in tumour development has been dis-
cussed and for tongue SCC a case of a young woman with 
both HPV18 and EBV infection has been reported [45]. The 
value of this co-infection is difficult to evaluate based on 
individual cases, but could indicate the importance of map-
ping not only HPV but also EBV status in these tumours. 
This is further supported by results from a recent study of 
nasopharyngeal carcinoma (NPC) indicating that a vaccine 
inducing antibodies against the EBV glycoprotein, gp350, as 
well as B-cell neutralizing antibodies, could reduce the risk 
of developing NPC and thus hopefully also other EBV-
related cancers [46]. Also other EBV-encoded proteins like 
EBNA1 and ZEBRA are promising therapeutic targets for 
treatment of EBV-infected cancers [47]. 
4.3. p63 
The individual members of the p63 family play important 
roles at different stages in formation of the oral mucosa [48, 
49, 50]. When studying their role in tumours, results from 
the whole group of SCCHN vary, with some showing p63 
expression to be correlated to poor outcome and aggressive 
behaviour [51, 52]. Looking at tongue SCC specifically, high 
expression of p63 correlates to poorer survival [53]. 
When treating p63 expressing tumours with cisplatin, the 
drug specifically degrades p63 and thereby withdraws an 
important signal for survival [54]. When exposing cells in 
vitro to cisplatin, p63 upregulates several miRNAs affecting 
DNA methylation. By inhibiting these miRNAs as well as 
the epigenetic enzymes they regulate, cisplatin resistant cells 
became more sensitive to cisplatin exposure [55]. As resis-
tance to cisplatin is a clinical problem, this finding could be 
of potential clinical relevance. 
PERSPECTIVES  
As pointed out previously, SCCHN is a heterogeneous 
group of tumours not only concerning site of origin but also 
regarding aetiology. Whereas smoking and alcohol are well 
known risk factors for tumours in many of these sites, UV-
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irradiation is the major risk factor for developing lip cancer, 
a tumour type often included in studies of SCCHN tumours. 
This pinpoints the very important fact that it is reasonable to 
include the whole group of SCCHN in analysis, but when it 
comes to interpretation of results dividing samples based on 
sub-site is a prerequisite for aiding new knowledge of poten-
tial value to the field of these tumours. Another important 
aspect is the need for inclusion of full clinical data ensuring 
complete control over how samples have been treated and 
handled.  
When it comes to evaluating data, many different sys-
tems are used, making it complicated or sometimes even 
impossible to compare findings between different research 
groups. One typical example being choice of scoring system 
in evaluation of immunohistochemical stainings. But before 
reaching that level of discrepancies between studies, it is 
important to state clearly how analyses were performed. In 
the case with immunohistochemical stainings, some use an 
automated staining machine whereas others perform manual 
staining. Conditions can be considered stable when using an 
automated staining machine, whereas in the case of manual 
staining many factors like ambient temperature, incubation 
time etc can influcence results. 
For the group of tongue SCC, with the increasing inci-
dence seen in young patients and particularly women, new 
data with impact on prognosis and treatment are urgently 
needed. But as long as data from analyses of several sub sites 
are presented as valid for the whole group of tumours, this 
vital point is missed.  
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